Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
Study Details
Study Description
Brief Summary
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
In this present study (COMP 004), the aim is to follow up participants from COMP 001 and COMP 003 in a long-term follow up study, with both remote and digital assessments, to explore the long term efficacy and safety of the three different doses of psilocybin (1 mg, 10 mg, and 25 mg) administered to patients with TRD as a monotherapy in COMP 001 and 25 mg psilocybin administered as an adjunct to an SSRI in COMP 003. Patients previously treated in COMP001 will be followed for approximately 40 weeks and patients previosuly treated in COMP003 will be followed for approximately 49 weeks giving a total follow up period of 52 weeks from psilocybin dosing.
Study Design
Outcome Measures
Primary Outcome Measures
- Long-term efficacy of psilocybin [up to 52 weeks]
Use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)
Secondary Outcome Measures
- Response, sustained response, remission and change in depression severity [Up to 52 weeks]
Montgomery Asberg Depression Rating Scale (MADRS)
- Psychosocial functioning and to predict durability of response to antidepressant treatment [up to 52 weeks]
Work and Social Adjustment Scale (WSAS) score change from Baseline of the prior study
- Functional impairment in work/school, social life, and family life. [Up to 52 weeks]
Sheehan Disability Scale (SDS) score change from Baseline of the prior study
- Safety of Psilocybin [Up to 52 weeks]
Incidence and severity of Adverse Events (AEs) and Seroius Adverse Events (SAEs)
Eligibility Criteria
Criteria
Inclusion Criteria:
Signed ICF Each participant having completed the final study visit of either COMP 001 or COMP 003 Ability to complete all protocol required assessment tools (including having access to the internet in order to complete the digital assessments) without any assistance or alteration to the copyrighted assessments, and to comply with all study visits
Exclusion Criteria:
Subject has any condition, for which in the opinion of the investigator, participation would not be in the interest of the subject eg participation could compromise the wellbeing of the participant or prevent, limit, or confound the protocol-specified assessments
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Kadima Neuropsychiatry Institute | La Jolla | California | United States | 92037 |
| 2 | Altman Clinical and Translational Research Institute, University of California | San Diego | California | United States | 92093 |
| 3 | Mood and Anxiety Disorders Program Emory University School of Medicine | Atlanta | Georgia | United States | 30329 |
| 4 | UT Center of Excellence on Mood Disorders, University of Texas Health Science Center | Houston | Texas | United States | 77054 |
| 5 | National Institute of Mental Health Czech Republic | Klecany | Czechia | ||
| 6 | Sheaf House, Tallaght Hospital | Dublin | Ireland | ||
| 7 | Groningen University Medical Centre | Groningen | Netherlands | ||
| 8 | Kings College London, Institute of Psychiatry, Psychology and Neurology | London | United Kingdom |
Sponsors and Collaborators
- COMPASS Pathways
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- COMP004